person · Reporting owner

MITCHELL DEAN J

Disclosed activity across 6 companies

Tapewire entity: 17741
SEC CIK: 0001199297

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662	President, U.S. Primary Care	September 10, 2003	September 12, 2003
PRECIGEN, INC.PGEN · Entity 4356	Director	March 14, 2024	March 18, 2024
Praxis Precision Medicines, Inc.PRAX · Entity 3538	Director	June 10, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date September 10, 2003 · Filed September 12, 2003

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	60,000	Reported balance After 2003-09-10 transaction · row 1 1 source row Row 1 · 2003-09-10 · Grant · Acquired 10,000 · Balance 60,000 F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy BMY Savings & Investment Program	567.86	Reported balance Holding disclosure · report date 2003-09-10 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 567.86 F2: Based on a plan statement as of the end of the most recent fiscal quarter.

Filing footnotes · ownership attribution and instrument terms

F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

F2: Based on a plan statement as of the end of the most recent fiscal quarter.

PRECIGEN, INC.

Report date March 14, 2024 · Filed March 18, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	503,183	Reported balance After 2024-03-14 transaction · row 1 1 source row Row 1 · 2024-03-14 · Grant · Acquired 39,510 · Balance 503,183 F1: The shares were issued to the reporting person in lieu of an annual retainer of $56,499.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	87,412	Reported balance After 2024-03-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-14 · Grant · Acquired 87,412 · Balance 87,412 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3: The RSUs vest in full on March 14, 2025.
Option to Purchase Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2034-03-14	Direct	101,626	Reported balance After 2024-03-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-14 · Grant · Acquired 101,626 · Balance 101,626

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued to the reporting person in lieu of an annual retainer of $56,499.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F3: The RSUs vest in full on March 14, 2025.

Praxis Precision Medicines, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,622	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 18,622 F1: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10	Direct	648	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Mitchell was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ImmunoGen, Inc.

Report date February 12, 2024 · Filed February 12, 2024

Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-02-12 transaction · row 1 1 source row Row 1 · 2024-02-12 · Disposition to issuer · Disposed 103,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-12 · Disposition to issuer · Disposed 142,667 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2024-11-11	Direct	Reported balance After 2024-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.07 · Expires 2025-11-10	Direct	Reported balance After 2024-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20	Direct	Reported balance After 2024-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16	Direct	Reported balance After 2024-02-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15	Direct	Reported balance After 2024-02-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14	Direct	Reported balance After 2024-02-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Kinnate Biopharma Inc.

Report date April 03, 2024 · Filed April 05, 2024

Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-08-18	Direct	Reported balance After 2024-04-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-04-03 · Disposition to issuer · Disposed 121,503 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.46 · Expires 2031-06-11	Direct	Reported balance After 2024-04-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13	Direct	Reported balance After 2024-04-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12	Direct	Reported balance After 2024-04-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Filing footnotes · ownership attribution and instrument terms

F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Theravance Biopharma, Inc.

Report date September 23, 2026 · Filed September 25, 2026

Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Ending reported balance After 2026-09-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-23 · Disposition to issuer · Disposed 91,204 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2028-04-30	Direct	Reported balance After 2026-09-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2029-04-29	Direct	Reported balance After 2026-09-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2030-04-27	Direct	Reported balance After 2026-09-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26	Direct	Reported balance After 2026-09-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-23 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.15 · Expires 2032-04-25	Direct	Reported balance After 2026-09-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-23 · Disposition to issuer · Disposed 28,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01	Direct	Reported balance After 2026-09-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07	Direct	Reported balance After 2026-09-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18	Direct	Reported balance After 2026-09-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11	Direct	Reported balance After 2026-09-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

Filing footnotes · ownership attribution and instrument terms

F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 14, 2023 Filed Jun 16, 2023 16:46 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantRestricted Stock Unit · Derivative	13,090	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-23-009949 · form4-06162023_080641.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,090 Underlying: Common Stock · 13,090 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F1 · price: The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date. F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date. Read SEC document
June 12, 2023 Filed Jun 13, 2023 18:30 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $3.48	$0.00	Disclosure SEC source: 0001209191-23-036865 · doc4.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 12, 2023 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date. Read SEC document
June 12, 2023 Filed Jun 14, 2023 11:12 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	28,981	$0.00 Strike: $0.96	$0.00	Disclosure SEC source: 0001689548-23-000106 · wf-form4_168674114401080.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,981 Underlying: Common Stock · 28,981 shares Expires 2033-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023. Read SEC document
May 02, 2023 Filed May 4, 2023 22:43 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	22,044	$0.00 Strike: $10.95	$0.00	Disclosure SEC source: 0001415889-23-007380 · form4-05042023_100558.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,044 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
May 02, 2023 Filed May 4, 2023 22:43 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	9,132	$0.00	$0.00	Disclosure SEC source: 0001415889-23-007380 · form4-05042023_100558.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,018 Read SEC document
March 24, 2023 Filed Mar 27, 2023 17:11 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	PurchaseCommon Stock	50,000	$0.84	$41,815.00	Disclosure SEC source: 0001104659-23-037022 · tm2310645-2_4seq1.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8297 to $0.8596, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth. Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:11 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	125,489	$0.00 Strike: $1.17	$0.00	Disclosure SEC source: 0000950103-23-004013 · dp190529_4-mitchell.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,489 Underlying: Common Stock · 125,489 shares Expires 2033-03-09 Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:11 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	106,837	$0.00	$0.00	Disclosure SEC source: 0000950103-23-004013 · dp190529_4-mitchell.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,837 Underlying: Common Stock · 106,837 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on March 9, 2024. F3 · derivative.expiration_date: The RSUs vest in full on March 9, 2024. Read SEC document
March 09, 2023 Filed Mar 13, 2023 21:11 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	48,290	$1.17	$56,499.30	Disclosure SEC source: 0000950103-23-004013 · dp190529_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,836 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
February 22, 2023 Filed Feb 25, 2023 01:07 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	61,576	$0.00	$0.00	Disclosure SEC source: 0000950103-23-003027 · dp189557_4-mitchell.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on February 22, 2023. F2 · derivative.expiration_date: The RSUs vested in full on February 22, 2023. Read SEC document
February 22, 2023 Filed Feb 25, 2023 01:07 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	61,576	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-003027 · dp189557_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
December 30, 2022 Filed Jan 4, 2023 16:21 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,024	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-23-000303 · form4-01042023_090125.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,667 Underlying: Common Stock · 3,024 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2022 Filed Oct 4, 2022 16:05 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,138	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-22-010213 · form4-10042022_011057.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,643 Underlying: Common Stock · 3,138 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 30, 2022 Filed Jul 5, 2022 16:49 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-22-007358 · form4-07052022_010738.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,505 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 15, 2022 Filed Jun 17, 2022 16:19 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	44,000	$3.37 Strike: $3.37	$148,280.00	Disclosure SEC source: 0001415889-22-006734 · form4-06172022_010606.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2032-06-15 F4 · derivative.exercise_date: Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 15, 2022 Filed Jun 17, 2022 16:19 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	15,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-22-006734 · form4-06172022_010606.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,172 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F2 · derivative.exercise_date: The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date. F3 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F3 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 13, 2022 Filed Jun 15, 2022 17:00 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantStock Option (right to buy) · Derivative	20,250	$0.00 Strike: $8.38	$0.00	Disclosure SEC source: 0001209191-22-037022 · doc4.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 20,250 shares Expires 2032-06-13 F1 · derivative.exercise_date: 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date. Read SEC document
June 08, 2022 Filed Jun 9, 2022 23:21 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	PurchaseCommon Stock	25,000	$1.81	$45,187.50	Disclosure SEC source: 0001689548-22-000075 · wf-form4_165481684513057.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.795 to $1.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth. Read SEC document
May 26, 2022 Filed May 27, 2022 21:26 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	22,753	$0.00 Strike: $8.38	$0.00	Disclosure SEC source: 0001689548-22-000066 · wf-form4_165368676658802.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,753 Underlying: Common Stock · 22,753 shares Expires 2032-05-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on May 26, 2022. Read SEC document
April 26, 2022 Filed Apr 29, 2022 01:04 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	28,000	$0.00 Strike: $10.15	$0.00	Disclosure SEC source: 0001415889-22-004332 · form4-04282022_060430.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
April 26, 2022 Filed Apr 29, 2022 01:04 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	9,852	$0.00	$0.00	Disclosure SEC source: 0001415889-22-004332 · form4-04282022_060430.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,886 Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:12 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,151	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-22-002536 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,172 Underlying: Common Stock · 3,151 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
March 25, 2022 Filed Mar 29, 2022 21:03 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	16,212	$0.00	$0.00	Disclosure SEC source: 0000950103-22-005401 · dp170040_4-mitchell.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 25, 2022. F2 · derivative.expiration_date: The RSUs vested in full on March 25, 2022. Read SEC document
March 25, 2022 Filed Mar 29, 2022 21:03 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	16,212	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-22-005401 · dp170040_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:49 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	83,189	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0000950103-22-003222 · dp167774_4-mitchell.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,189 Underlying: Common Stock · 83,189 shares Expires 2032-02-22 Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:49 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	61,576	$0.00	$0.00	Disclosure SEC source: 0000950103-22-003222 · dp167774_4-mitchell.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,576 Underlying: Common Stock · 61,576 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ('RSU") represents a contingent right to receive one share of Precigen common stock. F3 · derivative.exercise_date: The RSUs vest in full on February 22, 2023. F3 · derivative.expiration_date: The RSUs vest in full on February 22, 2023. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:49 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	27,832	$2.03	$56,498.96	Disclosure SEC source: 0000950103-22-003222 · dp167774_4-mitchell.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,758 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
December 31, 2021 Filed Jan 4, 2022 16:01 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,819	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-22-000099 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,021 Underlying: Common Stock · 1,819 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 30, 2021 Filed Oct 1, 2021 16:11 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,380	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-009040 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,202 Underlying: Common Stock · 2,380 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionStock Option (right to buy) · Derivative	50,000	$4.56 Strike: $4.56	$228,000.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · derivative · entry 8 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21, and 6/1/21, contingent upon the individual remaining a director as of each vesting date. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionStock Option (right to buy) · Derivative	18,000	$2.10 Strike: $2.10	$37,800.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · derivative · entry 7 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2029-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercisable as to 4,500 shares on each of 9/1/19, 12/1/19, 3/1/20, and 6/1/20, contingent upon the individual remaining a director as of each vesting date. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$4.64 Strike: $4.64	$46,400.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · derivative · entry 6 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Exercisable as to 2,500 shares on each of 9/1/17, 12/1/17, 3/1/18, and 6/1/18, contingent upon the individual remaining a director as of each vesting date. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$1.84 Strike: $1.84	$9,200.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · derivative · entry 5 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercisable as to 2,500 shares on each of 3/1/17 and 6/1/17, contingent upon the individual remaining a director as of each vesting date. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionCommon Stock	50,000	$4.56	$228,000.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · nonDerivative · entry 4 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionCommon Stock	18,000	$2.10	$37,800.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · nonDerivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionCommon Stock	10,000	$4.64	$46,400.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · nonDerivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2021 Filed Sep 3, 2021 16:06 UTC	ImmunoGen, Inc. IMGN · Entity 94428	Exercise / conversionCommon Stock	5,000	$1.84	$9,200.00	Disclosure SEC source: 0001179110-21-008587 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2021 Filed Jul 2, 2021 16:24 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	2,048	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-007320 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,822 Underlying: Common Stock · 2,048 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 16, 2021 Filed Jun 17, 2021 16:21 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	44,000	$6.77 Strike: $6.77	$297,880.00	Disclosure SEC source: 0001179110-21-006813 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2031-06-16 F4 · derivative.exercise_date: Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 16, 2021 Filed Jun 17, 2021 16:21 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	15,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-006813 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,774 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
June 11, 2021 Filed Jun 14, 2021 20:20 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantStock Option (right to buy) · Derivative	20,250	$0.00 Strike: $24.46	$0.00	Disclosure SEC source: 0001209191-21-040440 · doc4.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 20,250 shares Expires 2031-06-11 F1 · derivative.exercise_date: 1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 11, 2021 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date. Read SEC document
June 08, 2021 Filed Jun 9, 2021 21:05 UTC	Praxis Precision Medicines, Inc. PRAX · Entity 3538	GrantStock Option (Right to Buy) · Derivative	22,343	$0.00 Strike: $20.42	$0.00	Disclosure SEC source: 0001689548-21-000062 · wf-form4_162327272030058.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,343 Underlying: Common Stock · 22,343 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 8, 2021. Read SEC document
April 27, 2021 Filed Apr 29, 2021 22:13 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $20.35	$0.00	Disclosure SEC source: 0001179110-21-004700 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
April 27, 2021 Filed Apr 29, 2021 22:13 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	9,828	$0.00	$0.00	Disclosure SEC source: 0001179110-21-004700 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,034 Read SEC document
March 31, 2021 Filed Apr 2, 2021 13:01 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,666	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-21-004071 · edgar.xml · derivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,774 Underlying: Common Stock · 1,666 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest upon issuance. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
March 25, 2021 Filed Mar 29, 2021 23:48 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	22,107	$0.00 Strike: $7.71	$0.00	Disclosure SEC source: 0001123292-21-000567 · edgar.xml · derivative · entry 3 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,107 Underlying: Common Stock · 22,107 shares Expires 2031-03-25 Read SEC document
March 25, 2021 Filed Mar 29, 2021 23:48 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantRestricted Stock Units · Derivative	16,212	$0.00	$0.00	Disclosure SEC source: 0001123292-21-000567 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,212 Underlying: Common Stock · 16,212 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Precigen, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on March 25, 2022. F3 · derivative.expiration_date: The restricted stock units vest in full on March 25, 2022. Read SEC document
March 25, 2021 Filed Mar 29, 2021 23:48 UTC	PRECIGEN, INC. PGEN · Entity 4356	GrantCommon Stock	7,328	$7.71	$56,498.88	Disclosure SEC source: 0001123292-21-000567 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,926 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $56,500. Read SEC document
March 13, 2021 Filed Mar 16, 2021 20:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	62,189	$0.00	$0.00	Disclosure SEC source: 0001123292-21-000485 · edgar.xml · derivative · entry 2 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested in full on March 13, 2021. F2 · derivative.expiration_date: The RSUs vested in full on March 13, 2021. Read SEC document
March 13, 2021 Filed Mar 16, 2021 20:33 UTC	PRECIGEN, INC. PGEN · Entity 4356	Exercise / conversionCommon Stock	62,189	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-21-000485 · edgar.xml · nonDerivative · entry 1 MITCHELL DEAN J · CIK 0001199297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen, Inc. common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.